检索结果 - Karolyn Morris
- Showing 1 - 3 results of 3
-
1
-
2
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/... 由 Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R. Shustov, Brian G. Till, Chaitra S. Ujjani, Edward N. Libby, Mary Philip, Hilary Coye, Christen N. Martino, Sandra L Bhark, Karolyn Morris, Heather Rasmussen, Fatemeh Behnia, Jenna Voutsinas, Ajay K. Gopal
出版 2021Artigo -
3
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center 由 Aaron Lisberg, D. Andrew Tucker, Jonathan W. Goldman, Brian R. Wolf, James Carroll, Ariana Hardy, Karolyn Morris, Paulina Linares, Carlos Adame, Marshall L. Spiegel, Courtney Wells, Jordan R. McKenzie, Blanca Ledezma, Melody Mendenhall, Phillip Abarca, Krikor Bornazyan, J.S. Hunt, Nima Moghadam, Natalie Chong, Danielle Nameth, Caitlin Marx, John Madrigal, Sitaram Vangala, Narek Shaverdian, David Elashoff, Edward B. Garon
出版 2018Artigo
相关主题
Internal medicine
Medicine
Chemotherapy
Gastroenterology
Lymphoma
Oncology
Surgery
Adverse effect
Biology
Bone marrow
Brentuximab vedotin
Burkitt's lymphoma
CD30
Carboplatin
Center (category theory)
Chemistry
Chemotherapy regimen
Cisplatin
Crystallography
Cyclophosphamide
Etoposide
Ifosfamide
Immune system
Immunology
Lymphoblastic lymphoma
Mathematical economics
Mathematics
Mesna
Methotrexate
Outcome (game theory)